WO2012073047A3 - Compositions and methods - Google Patents
Compositions and methods Download PDFInfo
- Publication number
- WO2012073047A3 WO2012073047A3 PCT/GB2011/052399 GB2011052399W WO2012073047A3 WO 2012073047 A3 WO2012073047 A3 WO 2012073047A3 GB 2011052399 W GB2011052399 W GB 2011052399W WO 2012073047 A3 WO2012073047 A3 WO 2012073047A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions
- methods
- bcl11afor
- cancer
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
An inhibitor of BCL11Afor use in the prevention or treatment of cancer.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1020468.3 | 2010-12-03 | ||
GBGB1020468.3A GB201020468D0 (en) | 2010-12-03 | 2010-12-03 | Bcl11a |
GB1116340.9 | 2011-09-21 | ||
GBGB1116340.9A GB201116340D0 (en) | 2011-09-21 | 2011-09-21 | Compositions and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012073047A2 WO2012073047A2 (en) | 2012-06-07 |
WO2012073047A3 true WO2012073047A3 (en) | 2012-09-13 |
Family
ID=45099139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2011/052399 WO2012073047A2 (en) | 2010-12-03 | 2011-12-05 | Compositions and methods |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012073047A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX367081B (en) | 2012-08-29 | 2019-08-05 | Sangamo Biosciences Inc | Methods and compositions for treatment of a genetic condition. |
SG10201704008RA (en) | 2012-11-27 | 2017-06-29 | The Children's Medical Center Corp | Targeting Bcl11a Distal Regulatory Elements for Fetal Hemoglobin Reinduction |
CA2907694A1 (en) * | 2013-05-24 | 2014-11-27 | Roche Innovation Center Copenhagen A/S | Oligonucleotide modulators of b-cell cll/lymphoma 11a (bcl11a) and uses thereof |
CA2946309C (en) | 2014-04-25 | 2021-11-09 | Michael MILSOM | Synthetic bcl11a micrornas for treating hemoglobinopathies |
WO2016182917A1 (en) * | 2015-05-08 | 2016-11-17 | Children's Medical Center Corporation | Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction |
US11261441B2 (en) | 2017-03-29 | 2022-03-01 | Bluebird Bio, Inc. | Vectors and compositions for treating hemoglobinopathies |
WO2018218135A1 (en) | 2017-05-25 | 2018-11-29 | The Children's Medical Center Corporation | Bcl11a guide delivery |
GB201907999D0 (en) * | 2019-06-05 | 2019-07-17 | Cambridge Entpr | Breast cancer detection methods |
US20240165133A1 (en) * | 2020-07-02 | 2024-05-23 | Industry-Academic Cooperation Foundation, Yonsei University | Method for suppressing cancer metastasis through alteration of adhesion dependence of cancer cells |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006133923A2 (en) * | 2005-06-16 | 2006-12-21 | Bayer Healthcare Ag | Diagnosis, prognosis and prediction of recurrence of breast cancer |
WO2010030963A2 (en) * | 2008-09-15 | 2010-03-18 | Children's Medical Center Corporation | Modulation of bcl11a for treatment of hemoglobinopathies |
-
2011
- 2011-12-05 WO PCT/GB2011/052399 patent/WO2012073047A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006133923A2 (en) * | 2005-06-16 | 2006-12-21 | Bayer Healthcare Ag | Diagnosis, prognosis and prediction of recurrence of breast cancer |
WO2010030963A2 (en) * | 2008-09-15 | 2010-03-18 | Children's Medical Center Corporation | Modulation of bcl11a for treatment of hemoglobinopathies |
Non-Patent Citations (11)
Title |
---|
ARGOS M ET AL: "Genomewide scan for loss of heterozygosity and chromosomal amplification in breast carcinoma using single-nucleotide polymorphism arrays", CANCER GENETICS AND CYTOGENETICS, ELSEVIER SCIENCE PUBLISHING, NEW YORK, NY, US, vol. 182, no. 2, 15 April 2008 (2008-04-15), pages 69 - 74, XP022606023, ISSN: 0165-4608, [retrieved on 20080411], DOI: 10.1016/J.CANCERGENCYTO.2008.01.001 * |
B. YIN ET AL: "A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene", BLOOD, vol. 113, no. 5, 1 January 2008 (2008-01-01), pages 1075 - 1085, XP055017902, ISSN: 0006-4971, DOI: 10.1182/blood-2008-03-144436 * |
DEREK M. DYKXHOORN ET AL: "miR-200 Enhances Mouse Breast Cancer Cell Colonization to Form Distant Metastases", PLOS ONE, vol. 4, no. 9, 1 January 2009 (2009-01-01), pages E7181, XP055017967, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0007181 * |
DOUGHERTY C J ET AL: "Selective apoptosis of breast cancer cells by siRNA targeting of BORIS", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 370, no. 1, 23 May 2008 (2008-05-23), pages 109 - 112, XP022606115, ISSN: 0006-291X, [retrieved on 20080318], DOI: 10.1016/J.BBRC.2008.03.040 * |
HUANG SHIXIA ET AL: "Changes in gene expression during the development of mammary tumors in MMTV-Wnt-1 transgenic mice", GENOME BIOLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 6, no. 10, 30 September 2005 (2005-09-30), pages R84, XP021012944, ISSN: 1465-6906, DOI: 10.1186/GB-2005-6-10-R84 * |
JANG JI-YOUNG ET AL: "Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo", BREAST CANCER RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 10, no. 1, 12 February 2008 (2008-02-12), pages R11, XP021041293, ISSN: 1465-5411 * |
PENTAO LIU ET AL: "Bcl11a is essential for normal lymphoid development", NATURE IMMUNOLOGY, vol. 4, no. 6, 1 June 2003 (2003-06-01), pages 525 - 532, XP055017589, ISSN: 1529-2908, DOI: 10.1038/ni925 * |
SATTERWHITE E ET AL: "The BCL11 gene family: Involvement of BCL11A in lymphoid malignancies", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 98, no. 12, 1 December 2001 (2001-12-01), pages 3413 - 3420, XP002244631, ISSN: 0006-4971, DOI: 10.1182/BLOOD.V98.12.3413 * |
SONG CHOON LEE: "CHARACTERISATION OF BCL11 FUNCTIONS IN DEVELOPMENT USING GENETICALLY MODIFIED MICE", September 2008 (2008-09-01), Cambridge, UK, pages I-XX,264 - 278, XP002668289, Retrieved from the Internet <URL:ftp://ftp.sanger.ac.uk/pub4/theses/lee> [retrieved on 20120130] * |
YOHEI SHIMONO ET AL: "Downregulation of miRNA-200c Links Breast Cancer Stem Cells with Normal Stem Cells", CELL, vol. 138, no. 3, 1 August 2009 (2009-08-01), pages 592 - 603, XP055017610, ISSN: 0092-8674, DOI: 10.1016/j.cell.2009.07.011 * |
ZHIYUAN ZHANG ET AL: "Notch3 in Human Breast Cancer Cell Lines Regulates Osteoblast-Cancer Cell Interactions and Osteolytic Bone Metastasis", THE AMERICAN JOURNAL OF PATHOLOGY, vol. 177, no. 3, 1 September 2010 (2010-09-01), pages 1459 - 1469, XP055017782, ISSN: 0002-9440, DOI: 10.2353/ajpath.2010.090476 * |
Also Published As
Publication number | Publication date |
---|---|
WO2012073047A2 (en) | 2012-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1250061A1 (en) | Methods and compositions for the detection and treatment of preeclampsia | |
EP2877159B8 (en) | Efflux inhibitor compositions and methods of treatment using the same | |
WO2012073047A3 (en) | Compositions and methods | |
IL225471A0 (en) | Compositions and methods for the prevention and treatment of cancer | |
WO2008124660A3 (en) | Methods and compositions for the treatment of cancer | |
ZA201304638B (en) | Composition for use in the prevention and /or treatment of skin condition and skin diseases. | |
MX2015006478A (en) | Glutamase inhibitors and method of use. | |
IL206970A0 (en) | Compositions and methods for the treatment of tumor of hematopoietic origin | |
HK1159498A1 (en) | Methods and compositions for the treatment of cancer | |
GB201020860D0 (en) | Disulfiram formulation and uses thereof | |
EP2558085A4 (en) | Compositions and methods for the prevention and treatment of cancer | |
EP2340027A4 (en) | Methods and compositions for the treatment of cancer | |
WO2012082494A3 (en) | The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer | |
SI2391363T1 (en) | Compositions and methods for the treatment of cancer | |
HK1186680A1 (en) | Compositions comprising paulownin and or paulownia extracts and uses thereof | |
LT2576782T (en) | Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions | |
WO2010141956A3 (en) | Methods and compositions for the treatment of cancer | |
EP2150270A4 (en) | Methods and compositions for the treatment of cancer | |
EP2635273A4 (en) | Isoflavonoid compositions and methods for the treatment of cancer | |
WO2011130692A3 (en) | Androgen induced oxidative stress inhibitors | |
WO2012018597A9 (en) | Compositions and methods for enhancing the effectiveness of systemic, hipec, ip, and related cancer treatments | |
EP2547368A4 (en) | Methods and compositions for the treatment of cancer | |
WO2010120400A3 (en) | Substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carbonitriles and substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carboxamides as tubulin polymerization inhibitors | |
EP2411031A4 (en) | Methods and compositions for the treatment of cancer | |
EP2552452B8 (en) | EGFR inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11791627 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11791627 Country of ref document: EP Kind code of ref document: A2 |